Modeled Hepatic/Plasma Exposures of Fluvastatin Prescribed Alone in Subjects with Impaired Cytochrome P450 2C9*3 as One of Possible Determinant Factors Likely Associated with Hepatic Toxicity Reported in a Japanese Adverse Event Database.

Adachi, Koichiro; Ohyama, Katsuhiro; Tanaka, Yoichi; Saito, Yoshiro; Shimizu, Makiko; Yamazaki, Hiroshi

Adachi, Koichiro; Ohyama, Katsuhiro; Tanaka, Yoichi; Saito, Yoshiro; Shimizu, Makiko; Yamazaki, Hiroshi.

Affiliation

Adachi K; Showa Pharmaceutical University.
Ohyama K; School of Pharmacy, Tokyo University of Pharmacy and Life Sciences.
Tanaka Y; National Institute of Health Sciences.
Saito Y; National Institute of Health Sciences.
Shimizu M; Showa Pharmaceutical University.
Yamazaki H; Showa Pharmaceutical University.

Biol Pharm Bull ; 47(3): 635-640, 2024.

Article in En | MEDLINE | ID: mdl-38494736

Subject(s)

Drug-Related Side Effects and Adverse Reactions; Indoles; Humans; Fluvastatin/adverse effects; Cytochrome P-450 CYP2C9/genetics; Japan; Indoles/pharmacology; Cytochrome P-450 Enzyme System

Key words

CYP2C9.3; pharmacokinetic modeling; statin tolerance

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Drug-Related Side Effects and Adverse Reactions / Indoles Limits: Humans Country/Region as subject: Asia Language: En Journal: Biol Pharm Bull Journal subject: BIOQUIMICA / FARMACOLOGIA Year: 2024 Type: Article

Fulltext

XML

PubMed Links

Search on Google